SEL-212 Enters Phase III Clinical Trials Sansheng Pharmaceuticals receives a milestone payment of $4 million

On November 23rd Sansheng Pharmaceuticals announced that its partner, Selecta, had conducted phase III clinical trials of the combination therapy SEL-212 for chronic recurring gyration on behalf of Sobi™ and had paid a milestone payment of $4 million to Sansheng Pharmaceuticals.
phase III clinical trial completed its first patient medication in September 2020.
In 2014, Selecta was authorized by Sessyn Pharmaceuticals to develop SEL-212 using pegsiticase, a recombinant enzyme that metabolizes uric acid, and agreed to pay milestones and sales cash to Sansheng Pharmaceuticals during the clinical and future commercialization phase of the product.
SEL-212 includes pegsitase and ImTOR®immune tolerance platforms that provide long-lasting control of serum uric acid, reduce immunogenicity, and allow monthly re-dosing.
SEL-212 has the potential to reduce serum uric acid and MSU deposition in patients with chronic resusctic gyrations.
Recombinant uric acidase is highly immunogenic in the human body, and through Selecta's proprietary ImTOR platform, SEL-212 has the potential to reduce the formation of anti-drug antibodies, thus making it easy to give drugs once a month and improve the efficacy and tolerance of uric acidase.
29, 2020, Sobi and Selecta announced that they had reached a strategic licensing agreement for SEL-212, Selecta's research and development product.
under this partnership, Sobi is responsible for the development, registration and commercial activities of all markets except Greater China (including Chinese mainland, Hong Kong, Macau and Taiwan), while Selecta conducts Phase III research on Sobi's behalf.
note: There are deletions in the original text